PARP11 inhibition inactivates tumor-infiltrating regulatory T cells and improves the efficacy of immunotherapies.
Basavaraja R, Zhang H, Holczbauer Á, Lu Z, Radaelli E, Assenmacher CA, George SS, Nallamala VC, Beiting DP, Meyer-Ficca ML, Meyer RG, Guo W, Fan Y, Modzelewski AJ, Spiegelman VS, Cohen MS, Fuchs SY.
Basavaraja R, et al. Among authors: spiegelman vs.
Cell Rep Med. 2024 Jul 16;5(7):101649. doi: 10.1016/j.xcrm.2024.101649.
Cell Rep Med. 2024.
PMID: 39019005
Free PMC article.